Glooko, a leading provider of remote patient monitoring and digital health solutions for diabetes and chronic diseases announced the acquisition of xbird, a Berlin-based medical artificial intelligence company that develops JITAI (just-in-time adaptive interventions) technologies to help diabetic patients improve their therapy and make it accessible to as many people as possible.

Diabetes is affecting more and more people, especially type 2 diabetes. In the United States, the Centers for Disease Control and Prevention (CDC) estimates that 37.3 million people have diabetes (11.3% of the U.S. population), of whom 8.5 million (23.0% of adults) are undiagnosed. Even more alarming is the fact that 96 million people aged 18 years or older have prediabetes (38.0% of the U.S. adult population). Worldwide, there are approximately 537 million people with diabetes.

Patients with diabetes must manage their own glucose levels and insulin administration, monitor their diet and physical activity, and manage their stress. New solutions based on artificial intelligence are emerging to improve the management of diabetes, notably that of xbird.

XBIRD

Founded in 2015 by Sebastian Sujka and Matteo Carli, specializing in AI for the medical sector, xbird uses an AI-powered process to provide patients with personalized therapeutic support and improve compliance with treatment prescription. The company captures 24-hour data streams from embedded sensors on smartphones, wearable devices and medical devices to develop algorithms and machine learning models that process these streams into real-time just-in-time adaptive interventions (JITAI).

GLOOKO

Glooko’s mission is to improve the lives of people with diabetes and related chronic diseases by connecting them with their caregivers and equipping them with the tools necessary to achieve positive outcomes, increased access, improved satisfaction and reduced costs.
The company’s software platforms collect and analyze data from blood glucose meters, CGMs (continuous glucose monitoring), insulin pumps, connected insulin pens, blood pressure cuffs, nutrition apps, connected scales and activity trackers. The information is then stored in one highly secure location, allowing for easy remote download via app or in-clinic, and produces easy-to-read analytics with actionable charts and graphs.

Glooko intends to integrate the xbird JITAI personalized digital coaching software into its platform adopted by over 7,500 clinics worldwide and over 1 million users, expanding its capabilities and analytics.

Russ Johannesson, CEO of Glooko states:

“We are thrilled to welcome the xbird team to the Glooko family. Our investment in xbird represents Glooko’s strategic commitment to machine learning and personalized digital coaching for patients with chronic diseases. Among the many JITAI companies in the digital health landscape, xbird clearly has a superior solution and has established successful partnerships with diabetes monitoring device manufacturers and clinical facilities. The combination of Glooko’s established global footprint and xbird’s exciting JITAI capabilities will enable us to improve patient outcomes.”

Sebastian Sujka, CEO and co-founder of xbird, will join Glooko where he will be Managing Director of Glooko GmbH, along with the entire xbird team.

“xbird and Glooko are an ideal fit. We share a commitment to providing solutions that address multiple chronic diseases and produce measurable results, and we have a common mission to globally serve all patients with needs. Our goal is to continue to design digital health solutions for people living with these diseases and make our capabilities accessible to as many patients as possible.”

Translated from Glooko acquiert xbird, société allemande spécialisée dans l’IA et la gestion du diabète